Your browser doesn't support javascript.
loading
Diagnosis, treatment and burden in advanced ovarian cancer: a UK real-world survey of healthcare professionals and patients.
Tookman, Laura; Green, Clare; Leonard, Katy; Clare, Victoria; Patel, Nafisa; Dunlop, Farah; McCormack, Stephen; Ellis, Hilary; de Courcy, Joanna; Bateman, Lauren; Borley, Jane.
Afiliação
  • Tookman L; Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Green C; University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Leonard K; GlaxoSmithKline, Middlesex, UK.
  • Clare V; Ovacome, London, UK.
  • Patel N; Leicester Royal Infirmary Hospital, Leicester, UK.
  • Dunlop F; GlaxoSmithKline, Middlesex, UK.
  • McCormack S; GlaxoSmithKline, Middlesex, UK.
  • Ellis H; Adelphi Real World, Bollington, UK.
  • de Courcy J; Adelphi Real World, Bollington, UK.
  • Bateman L; Adelphi Real World, Bollington, UK.
  • Borley J; Royal Cornwall Hospitals NHS Trust, Truro, UK.
Future Oncol ; 20(23): 1657-1673, 2024.
Article em En | MEDLINE | ID: mdl-39229967
ABSTRACT

Aim:

Little is known regarding uptake of epithelial ovarian cancer (EOC) treatments or patient burden in UK real-world practice.

Methods:

Cross-sectional surveys of patients with advanced EOC and healthcare professionals (HCPs).

Results:

101 HCPs and 142 patients participated. Time from initial primary care consultation to diagnosis was ∼7 weeks. 83% patients were offered hereditary genetic testing, with 89% uptake. 53% HCPs reported surgery was performed ≤1 month in non-neoadjuvant setting. Surgery delay negatively impacted patient quality of life (61%), mental health (89%), and surgical outcomes (63%). 56% patients received active first-line maintenance treatment; patients on active surveillance had greater emotional/psychological distress.

Conclusion:

Treatment delays and low uptake of active first-line treatment should be addressed. Emotional support must be readily accessible throughout treatment.
What is this article about? New treatments for ovarian cancer mean that patients could be treated and live with the disease for many years. However, not much is known about the treatments that are actually received by patients with ovarian cancer in real-life. These surveys were done to learn more about the treatment and experience of patients with ovarian cancer in the UK.What were the results? 101 healthcare professionals (HCPs) and 142 patients took the surveys. The surveys found that patients usually waited about 7 weeks from their first GP visit to diagnosis of ovarian cancer. Half of HCPs reported that patients had surgery within 1 month of the decision that surgery was needed. HCPs reported that delays in surgery had a negative impact on patient quality of life, mental health, and the success of the surgery. After finishing their first line of chemotherapy, about half of patients had a maintenance treatment to control their ovarian cancer and give them as long as possible between recurrences. The remaining patients were not given treatment but were watched for further signs of cancer. Patients on maintenance treatment experienced less emotional/psychological distress than those managed by watchful waiting.What do the results of the study mean? This survey shows that more needs to be done to make sure that patients with ovarian cancer in the UK are diagnosed and treated quickly and offered the right treatment. Emotional support should be available to patients during their treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Qualidade de Vida / Pessoal de Saúde / Carcinoma Epitelial do Ovário Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Future Oncol / Future oncol / Future oncology Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Qualidade de Vida / Pessoal de Saúde / Carcinoma Epitelial do Ovário Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Future Oncol / Future oncol / Future oncology Ano de publicação: 2024 Tipo de documento: Article